Genmab A/S (GMAB): Price and Financial Metrics

Genmab A/S (GMAB)

Today's Latest Price: $34.34 USD

0.67 (1.99%)

Updated Oct 29 4:00pm

Add GMAB to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

GMAB Stock Summary

  • With a one year PEG ratio of 0.21, Genmab A is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.51% of US stocks.
  • Of note is the ratio of Genmab A's sales and general administrative expense to its total operating expenses; merely 6.32% of US stocks have a lower such ratio.
  • GMAB's price/sales ratio is 27.77; that's higher than the P/S ratio of 93.92% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Genmab A, a group of peers worth examining would be TLC, SPRO, HCM, AFMD, and ERYP.
  • GMAB's SEC filings can be seen here. And to visit Genmab A's official web site, go to

GMAB Stock Price Chart Interactive Chart >

Price chart for GMAB

GMAB Price/Volume Stats

Current price $34.34 52-week high $38.87
Prev. close $33.67 52-week low $16.24
Day low $33.91 Volume 547,400
Day high $34.64 Avg. volume 667,804
50-day MA $36.65 Dividend yield N/A
200-day MA $29.78 Market Cap 22.49B

Genmab A/S (GMAB) Company Bio

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

GMAB Latest News Stream

Event/Time News Detail
Loading, please wait...

GMAB Latest Social Stream

Loading social stream, please wait...

View Full GMAB Social Stream

Latest GMAB News From Around the Web

Below are the latest news stories about Genmab A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.

Agenus Vs. Seattle Genetics Cervical Cancer Clinical Trial Results

Seattle Genetics (SGEN) is a large-cap biotech pharmaceutical company with commercial product revenue now running over $1 billion annually. Genmab (GMAB) is its partner for tisotumab vedotin, a potential therapy for recurrent or metastatic cervical cancer, and received $0.5 billion in royalties in 2019, mostly for Darzalex. A rival in...

William Meyers on Seeking Alpha | September 30, 2020

InSysBio partners with Genmab in solid tumours

InSysBio collaborates with Genmab ([[GMAB]] -8.8%) for GEN1042, a bispecific agonistic antibody for solid tumors.The key aim of this collaboration is to develop a quantitative system pharmacology ((QSP)) model that allows exploration of the relationships between dose, schedule, and tumor response in patients treated with this novel agent. Moreover, InSysBio has...

Seeking Alpha | September 23, 2020

Genmab shares drop on legal battle with J&J over cancer drug

Shares in Danish biotech firm Genmab fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson over royalty payments for its key cancer drug.

Reuters Latin America | September 23, 2020

Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent and/or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Patients had previously received a doublet chemotherapy and, if eligible, bevacizumab as fir

Business Wire | September 21, 2020

Seattle Genetics/Genmab antibody-drug conjugate shows positive effect in cervical cancer (NASDAQ:GMAB)

Genmab A/S (GMAB -1.3%) and development partner Seattle Genetics (SGEN -1.7%) announce positive results from a Phase 2 clinical trial, innovaTV 204, evalua

Seeking Alpha | September 21, 2020

Read More 'GMAB' Stories Here

GMAB Price Returns

1-mo -6.20%
3-mo 0.44%
6-mo 37.36%
1-year 57.16%
3-year 70.08%
5-year 245.47%
YTD 53.78%
2019 35.54%
2018 -0.61%
2017 -0.04%
2016 23.73%
2015 128.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7123 seconds.